Stocktoria

Monopar Therapeutics MNPR

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2019-12-19 · LEI

Monopar Therapeutics statistics & valuation

Market cap$587.4M
P / B4.3×
Return on equity-10.0%
Return on capital-12.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2019202020212022202320242025202520252025
Operating margin (%)
2019202020212022202320242025202520252025
Return on equity (%)
-33.50% -40.20% -48.10% -104.20% -150.40% -28.30% -10.00% 2019202020212022202320242025202520252025
Shares outstanding
10.6M 11.5M 12.6M 12.9M 3.0M 6.1M 6.1M 6.1M 6.7M 7.4M 2019202020212022202320242025202520252025
Net debt ($)
2019202020212022202320242025202520252025
Share buybacks ($)
2019202020212022202320242025202520252025
Return on assets (%)
-31.60% -37.40% -44.40% -79.50% -114.40% -25.90% -9.70% 2019202020212022202320242025202520252025
Free cash flow margin (%)
2019202020212022202320242025202520252025
Debt / equity (×)
2019202020212022202320242025202520252025
EPS ($)
2019202020212022202320242025202520252025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2025FY2025FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Return on assets-9.7%———-25.9%-114.4%-79.5%-44.4%-37.4%-31.6%
Return on equity-10.0%———-28.3%-150.4%-104.2%-48.1%-40.2%-33.5%
Current ratio51.3556.1033.94—11.474.174.2112.9814.2818.27

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.